Trials / Completed
CompletedNCT01741545
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pegylated-Interferon-lambda | |
| DRUG | Ribavirin | |
| DRUG | Daclatasvir |
Timeline
- Start date
- 2013-03-31
- Primary completion
- 2015-01-31
- Completion
- 2015-01-31
- First posted
- 2012-12-05
- Last updated
- 2020-08-11
- Results posted
- 2019-06-24
Locations
32 sites across 8 countries: United States, Australia, France, Italy, Netherlands, Romania, Russia, Spain
Source: ClinicalTrials.gov record NCT01741545. Inclusion in this directory is not an endorsement.